Brown Advisory’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $473K | Sell |
2,086
-95
| -4% | -$16.9K | ﹤0.01% | 1151 |
|
|
2026
Q1 | $376K | Buy |
2,181
+9
| +0.4% | +$1.67K | ﹤0.01% | 1146 |
|
|
2025
Q4 | $433K | Sell |
2,172
-77
| -3% | -$14K | ﹤0.01% | 1102 |
|
|
2025
Q3 | $352K | Sell |
2,249
-84
| -4% | -$13.3K | ﹤0.01% | 1160 |
|
|
2025
Q2 | $354K | Buy |
2,333
+114
| +5% | +$15.2K | ﹤0.01% | 1105 |
|
|
2025
Q1 | $334K | Sell |
2,219
-12,506
| -85% | -$2.1M | ﹤0.01% | 1097 |
|
|
2024
Q4 | $2.72M | Sell |
14,725
-793
| -5% | -$153K | ﹤0.01% | 600 |
|
|
2024
Q3 | $3.06M | Sell |
15,518
-1,128
| -7% | -$234K | ﹤0.01% | 580 |
|
|
2024
Q2 | $3.44M | Buy |
16,646
+944
| +6% | +$214K | ﹤0.01% | 542 |
|
|
2024
Q1 | $4.25M | Buy |
15,702
+968
| +7% | +$231K | 0.01% | 518 |
|
|
2023
Q4 | $3.48M | Sell |
14,734
-179
| -1% | -$35.2K | ﹤0.01% | 537 |
|
|
2023
Q3 | $2.92M | Buy |
14,913
+117
| +0.8% | +$24K | ﹤0.01% | 544 |
|
|
2023
Q2 | $3.11M | Sell |
14,796
-152,194
| -91% | -$30.3M | ﹤0.01% | 541 |
|
|
2023
Q1 | $33.7M | Buy |
166,990
+1,482
| +0.9% | +$336K | 0.06% | 255 |
|
|
2022
Q4 | $36.1M | Sell |
165,508
-19,315
| -10% | -$4.22M | 0.07% | 236 |
|
|
2022
Q3 | $36.4M | Sell |
184,823
-3,917
| -2% | -$846K | 0.07% | 219 |
|
|
2022
Q2 | $40.4M | Sell |
188,740
-90,239
| -32% | -$22M | 0.08% | 209 |
|
|
2022
Q1 | $79.2M | Sell |
278,979
-360,156
| -56% | -$111M | 0.12% | 139 |
|
|
2021
Q4 | $241M | Sell |
639,135
-48,216
| -7% | -$18.7M | 0.3% | 74 |
|
|
2021
Q3 | $284M | Sell |
687,351
-85,090
| -11% | -$35.3M | 0.42% | 65 |
|
|
2021
Q2 | $286M | Sell |
772,441
-109,207
| -12% | -$36.5M | 0.43% | 63 |
|
|
2021
Q1 | $256M | Buy |
881,648
+24,669
| +3% | +$6.86M | 0.44% | 61 |
|
|
2020
Q4 | $214M | Sell |
856,979
-3,324
| -0.4% | -$792K | 0.38% | 65 |
|
|
2020
Q3 | $195M | Sell |
860,303
-126,332
| -13% | -$26.2M | 0.4% | 64 |
|
|
2020
Q2 | $172M | Buy |
986,635
+52,733
| +6% | +$8.42M | 0.4% | 61 |
|
|
2020
Q1 | $118M | Buy |
933,902
+16,904
| +2% | +$2.54M | 0.36% | 65 |
|
|
2019
Q4 | $140M | Buy |
916,998
+6,071
| +0.7% | +$841K | 0.36% | 61 |
|
|
2019
Q3 | $121M | Buy |
910,927
+63,007
| +7% | +$8.45M | 0.34% | 65 |
|
|
2019
Q2 | $120M | Buy |
847,920
+616
| +0.1% | +$83.5K | 0.34% | 63 |
|
|
2019
Q1 | $123M | Buy |
847,304
+48,076
| +6% | +$6.32M | 0.35% | 64 |
|
|
2018
Q4 | $90.5M | Buy |
799,228
+7,663
| +1% | +$959K | 0.3% | 62 |
|
|
2018
Q3 | $106M | Buy |
791,565
+89,065
| +13% | +$11M | 0.3% | 65 |
|
|
2018
Q2 | $78.9M | Buy |
702,500
+36,219
| +5% | +$3.92M | 0.24% | 84 |
|
|
2018
Q1 | $71.1M | Buy |
666,281
+12,227
| +2% | +$1.32M | 0.23% | 87 |
|
|
2017
Q4 | $71.6M | Sell |
654,054
-30,342
| -4% | -$3.3M | 0.23% | 94 |
|
|
2017
Q3 | $73.9M | Sell |
684,396
-86,523
| -11% | -$8.89M | 0.25% | 92 |
|
|
2017
Q2 | $78M | Buy |
770,919
+19,350
| +3% | +$1.78M | 0.24% | 89 |
|
|
2017
Q1 | $67.6M | Buy |
751,569
+45,803
| +6% | +$3.89M | 0.23% | 97 |
|
|
2016
Q4 | $53.8M | Buy |
705,766
+163,992
| +30% | +$12.5M | 0.19% | 103 |
|
|
2016
Q3 | $45.2M | Buy |
541,774
+38,938
| +8% | +$3.26M | 0.16% | 115 |
|
|
2016
Q2 | $41.5M | Buy |
502,836
+7,074
| +1% | +$583K | 0.15% | 121 |
|
|
2016
Q1 | $37.6M | Sell |
495,762
-7,031
| -1% | -$520K | 0.13% | 120 |
|
|
2015
Q4 | $40.4M | Buy |
502,793
+17,634
| +4% | +$1.27M | 0.14% | 111 |
|
|
2015
Q3 | $30.8M | Buy |
485,159
+24,885
| +5% | +$1.79M | 0.11% | 135 |
|
|
2015
Q2 | $32.4M | Sell |
460,274
-55,373
| -11% | -$4.1M | 0.11% | 137 |
|
|
2015
Q1 | $40.9M | Sell |
515,647
-19,837
| -4% | -$1.46M | 0.13% | 117 |
|
|
2014
Q4 | $34.1M | Sell |
535,484
-52,784
| -9% | -$3.31M | 0.11% | 142 |
|
|
2014
Q3 | $35.1M | Sell |
588,268
-1,938
| -0.3% | -$111K | 0.11% | 135 |
|
|
2014
Q2 | $31.6M | Buy |
590,206
+41,852
| +8% | +$2.3M | 0.1% | 142 |
|
|
2014
Q1 | $33.1M | Buy |
548,354
+34,224
| +7% | +$1.99M | 0.11% | 140 |
|
|
2013
Q4 | $27.3M | Buy |
514,130
+39,503
| +8% | +$1.98M | 0.09% | 152 |
|
|
2013
Q3 | $22M | Buy |
474,627
+49,805
| +12% | +$2.29M | 0.08% | 162 |
|
|
2013
Q2 | $17.4M | Buy |
+424,822
| New | +$18.2M | 0.07% | 166 |
|
Other funds holding CRL
AI
Brown Advisory's CRL Position: Q2 2026 in Review
Brown Advisory reduced its Charles River Laboratories (CRL) stake by 4.4% in Q2 2026, selling an estimated $16.9K and leaving 2,086 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #1151.
Brown Advisory first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $286M in Q2 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Brown Advisory held 2,086 shares of Charles River Laboratories worth $473K as of Q2 2026.
- Brown Advisory sold 95 Charles River Laboratories shares in Q2 2026, an estimated $16.9K.
- Charles River Laboratories made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1151 holding.
- Brown Advisory first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- Brown Advisory's Charles River Laboratories position peaked at $286M in Q2 2021.
- 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.